Bioauxilium

BioAuxilium is a Canadian biotechnology company founded by seasoned scientists from PerkinElmer. It focuses on the design, development and manufacturing of top-quality, fully-validated assay kits that simplify laboratory workflow and accelerate biomedical research. Since its inception in 2013, Bioauxilium has licensed hundreds of TR FRET assay kits enabling the quantification of cellular proteins and biomarkers. BioAuxilium’s kits are based on its proprietary THUNDER™ TR-FRET technology. They are offered at an outstanding value and are supported by expert technical support.

View All BioAuxilium Products

More information about BioAuxilium

BioAuxilium founders have over 20 years of academic and industry experience. They have a renowned expertise in the design, development and manufacturing of assay kits and reagents on the most popular technology platforms available (e.g., TR-FRET, AlphaScreen®/AlphaLISA®, BRET/BRET2, FP, Aequorin and more).

BioAuxilium is based in Montréal (Canada) and located within NEOMED’s state-of-the-art laboratories and core facilities where the company provides a wide range of product and assay development services to academic and industry research groups.

New THUNDER™ TR-FRET Toolbox Reagents

BioAuxilium have released their new range of products - the THUNDER™ TR-FRET Toolbox Reagents!

These reagents are used by drug discovery scientists to design TR-FRET assays using anti-tag and/or streptavidin labelled with either the donor (Europium chelate) or the acceptor (far-red dye) fluorophores.

Find Out More

Why BioAuxilium is best in the business

A DIRECT COMPARISON OF THUNDER™ ASSAY PERFORMANCE WITH TWO EXISTING TR-FRET PLATFORMS

We compared head- to-head the performance of THUNDER™ with two existing TR-FRET assay technologies. Six endogenous phosphorylated proteins were measured in lysates from cells treated with pathway-specific modulators.

THUNDER™ phospho-protein assays exhibit superior or comparable performance at a lower cost per well.

BioAuxilium has recently introduced THUNDER™, a new immunoassay platform based on an enhanced TR-FRET technology. The THUNDER™ Cell Signaling Assay Kits are designed to measure endogenous levels of specific intracellular phosphorylated proteins with high sensitivity, specificity, robustness and cost effectiveness. The aim of this Application Note was to compare head-to-head the performance of THUNDER™ in 384-well plate format with two existing TR-FRET technologies (Companies A and B) measuring a panel of six phosphorylated proteins. The three TR-FRET assay technology
platforms were evaluated for their capacity to measure relative levels of phosphorylated 4EBP1 (T37/T46), AKTpan (S473), ERK1/2 (T202/ Y204) p38αβγ (T180/Y182), SLP-76 (S376) and STAT3 (Y705) in wholecell lysates from cells treated with pathway-specific modulators.